SI2412828T1 - Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr - Google Patents
Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfrInfo
- Publication number
- SI2412828T1 SI2412828T1 SI200831031T SI200831031T SI2412828T1 SI 2412828 T1 SI2412828 T1 SI 2412828T1 SI 200831031 T SI200831031 T SI 200831031T SI 200831031 T SI200831031 T SI 200831031T SI 2412828 T1 SI2412828 T1 SI 2412828T1
- Authority
- SI
- Slovenia
- Prior art keywords
- ras
- egfr antibody
- antibody therapy
- raf mutations
- raf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90697607P | 2007-03-13 | 2007-03-13 | |
EP11184356.1A EP2412828B1 (en) | 2007-03-13 | 2008-03-11 | K-ras and B-raf mutations and anti-EGFr antibody therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2412828T1 true SI2412828T1 (sl) | 2013-10-30 |
Family
ID=39666021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200831031T SI2412828T1 (sl) | 2007-03-13 | 2008-03-11 | Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr |
Country Status (20)
Country | Link |
---|---|
US (2) | US20090075267A1 (sl) |
EP (2) | EP2118322A2 (sl) |
JP (3) | JP2010521154A (sl) |
AR (1) | AR065686A1 (sl) |
AU (1) | AU2008226808B2 (sl) |
CA (1) | CA2680330A1 (sl) |
CL (1) | CL2008000716A1 (sl) |
CY (1) | CY1114159T1 (sl) |
DK (1) | DK2412828T3 (sl) |
ES (1) | ES2426814T3 (sl) |
HK (1) | HK1167005A1 (sl) |
HR (1) | HRP20130764T1 (sl) |
MX (1) | MX2009009779A (sl) |
PE (1) | PE20090690A1 (sl) |
PL (1) | PL2412828T3 (sl) |
PT (1) | PT2412828E (sl) |
RS (1) | RS52932B (sl) |
SI (1) | SI2412828T1 (sl) |
TW (1) | TW200904828A (sl) |
WO (1) | WO2008112274A2 (sl) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2620195A1 (en) * | 2005-08-24 | 2007-03-01 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
ITBO20050646A1 (it) | 2005-10-26 | 2007-04-27 | Silicon Biosystem S R L | Metodo ed apparato per la caratterizzazione ed il conteggio di particelle |
US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
EP3399450A1 (en) | 2006-05-18 | 2018-11-07 | Caris MPI, Inc. | System and method for determining individualized medical intervention for a disease state |
EP2118322A2 (en) * | 2007-03-13 | 2009-11-18 | Amgen Inc. | K-ras and b-raf mutations and anti-egfr antibody therapy |
CA2680326A1 (en) * | 2007-03-13 | 2008-09-18 | Amgen Inc. | K-ras mutations and anti-egfr antibody therapy |
ITTO20070771A1 (it) | 2007-10-29 | 2009-04-30 | Silicon Biosystems Spa | Metodo e apparato per la identificazione e manipolazione di particelle |
EP3216874A1 (en) | 2008-09-05 | 2017-09-13 | TOMA Biosciences, Inc. | Methods for stratifying and annotating cancer drug treatment options |
IT1391619B1 (it) | 2008-11-04 | 2012-01-11 | Silicon Biosystems Spa | Metodo per l'individuazione, selezione e analisi di cellule tumorali |
US10895575B2 (en) | 2008-11-04 | 2021-01-19 | Menarini Silicon Biosystems S.P.A. | Method for identification, selection and analysis of tumour cells |
EP3181705A1 (en) | 2008-11-12 | 2017-06-21 | Caris Life Sciences Switzerland Holdings GmbH | Methods and systems of using exosomes for determining phenotypes |
WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
JP2012517238A (ja) * | 2009-02-11 | 2012-08-02 | カリス エムピーアイ インコーポレイテッド | 腫瘍の分子プロファイリング法 |
CN101487051B (zh) * | 2009-02-24 | 2011-07-20 | 广州益善生物技术有限公司 | Braf基因突变的检测探针、液相芯片及其检测方法 |
CA2782123C (en) | 2009-03-17 | 2017-05-02 | Silicon Biosystems S.P.A. | Microfluidic device for isolation of cells |
AU2010289794B2 (en) * | 2009-08-24 | 2014-10-02 | Genentech, Inc. | Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels |
WO2011031840A1 (en) * | 2009-09-09 | 2011-03-17 | Quintiles Transnational Corp. | Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders |
CN102115782B (zh) * | 2009-12-30 | 2014-06-18 | 北京雅康博生物科技有限公司 | 用于定量检测K-ras突变的试剂盒 |
WO2011109584A2 (en) * | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
JP2013523178A (ja) * | 2010-04-12 | 2013-06-17 | レスポンス ジェネティクス,インコーポレイティド | Krasプライマーおよびプローブ |
EP2582837A1 (en) | 2010-06-15 | 2013-04-24 | Alberto Bardelli | Mlk4 gene, a new diagnostic and prognostic marker in cancers |
KR20130113447A (ko) | 2010-09-24 | 2013-10-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화 |
WO2012049279A1 (en) | 2010-10-14 | 2012-04-19 | Universitaet Des Saarlandes | MEANS AND METHODS APPLYING SINGLE NUCLEOTIDE PRIMER EXTENSION WITH ION PAIR-, REVERSED-PHASE HPLC (SIRPH) FOR THE DIAGNOSIS OF SNPs |
US8628773B2 (en) | 2011-04-07 | 2014-01-14 | Amgen Inc. | Antigen binding proteins |
ITTO20110990A1 (it) | 2011-10-28 | 2013-04-29 | Silicon Biosystems Spa | Metodo ed apparato per l'analisi ottica di particelle a basse temperature |
US9023640B2 (en) * | 2011-12-13 | 2015-05-05 | Fundamental Solutions Corporation | Device for rapid detection of infectious agents |
KR20220165811A (ko) | 2012-08-17 | 2022-12-15 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
CA2886397A1 (en) * | 2012-09-26 | 2014-04-03 | Insight Genetics, Inc. | Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers |
EP2977464A4 (en) * | 2013-03-19 | 2016-10-19 | Toppan Printing Co Ltd | PROCEDURE FOR PREDICTING SENSITIVITY TO EGFR HEMMER |
JP6512828B2 (ja) | 2014-01-07 | 2019-05-15 | 三星電子株式会社Samsung Electronics Co.,Ltd. | c−Met阻害剤の効能予測または効能検証のためのバイオマーカー |
EP3805404A1 (en) * | 2014-05-13 | 2021-04-14 | Board of Regents, The University of Texas System | Gene mutations and copy number alterations of egfr, kras and met |
KR20160037666A (ko) | 2014-09-29 | 2016-04-06 | 삼성전자주식회사 | KRAS 또는 BRAF의 변이를 이용한 c-Met 저해제의 효능 예측 |
US10471183B2 (en) | 2015-12-22 | 2019-11-12 | Access Vascular, Inc. | High strength biomedical materials |
EP3641842A4 (en) | 2017-06-21 | 2021-03-17 | Access Vascular, Inc. | HIGH STRENGTH POROUS MATERIALS WITH WATER-SOLUBLE POLYMERS |
CN107918013A (zh) * | 2017-09-25 | 2018-04-17 | 浙江天科高新技术发展有限公司 | 化学发光酶免测定循环肿瘤细胞中K‑Ras蛋白的方法及试剂盒 |
CN108085390A (zh) * | 2017-12-29 | 2018-05-29 | 上海桐树生物科技有限公司 | 肿瘤驱动基因变异的检测剂、检测试剂盒及其应用 |
JP2023533506A (ja) | 2020-06-30 | 2023-08-03 | アクセス・バスキュラー・インコーポレイテッド | マーキングを含む物品および関連する方法 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
US5470705A (en) | 1992-04-03 | 1995-11-28 | Applied Biosystems, Inc. | Probe composition containing a binding domain and polymer chain and methods of use |
WO1993020236A1 (en) | 1992-04-03 | 1993-10-14 | Applied Biosystems, Inc. | Probe composition and method |
ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
JP3628614B2 (ja) | 1999-03-15 | 2005-03-16 | アプレラ コーポレイション | 多重核酸検出のためのプローブ/移動度モディファイア複合体 |
JP2004507226A (ja) | 2000-05-30 | 2004-03-11 | ピーイー コーポレイション (エヌワイ) | ライゲーションおよび増幅の組み合わせを用いて標的核酸を検出するための方法 |
US6503914B1 (en) * | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
MXPA04011550A (es) | 2002-05-20 | 2005-02-17 | Abgenix Inc | Tratamiento de carcinoma renal utilizando anticuerpos contra el receptor del factor de crecimiento epidermico. |
CN102586431B (zh) * | 2004-03-31 | 2015-04-22 | 综合医院公司 | 测定癌症对表皮生长因子受体靶向性治疗反应性的方法 |
CA2569520C (en) | 2004-06-04 | 2023-03-14 | Genentech, Inc. | Kras mutations for identifying colorectal tumors responsive to cetuximab or panitumumab |
US7981605B2 (en) * | 2005-02-24 | 2011-07-19 | Amgen Inc. | Epidermal growth factor receptor mutations |
WO2006107854A2 (en) * | 2005-04-01 | 2006-10-12 | Amgen Inc. | Epidermal growth factor receptor gene copy number |
KR20080003422A (ko) * | 2005-04-14 | 2008-01-07 | 메르크 파텐트 게엠베하 | 종양 조직 내의 egfr 유전자의 증가된 복제수에 기초한항-egfr 항체 치료 |
PL1913157T5 (pl) * | 2005-06-28 | 2017-09-29 | Genentech Inc | Mutacje EGFR i KRAS do prognozowania reakcji pacjenta na leczenie inhibitorem EGFR |
WO2007109571A2 (en) * | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
BRPI0716646B1 (pt) * | 2006-08-10 | 2018-07-31 | Ubukata Industries Co., Ltd. | Comutador de resposta térmica |
CA2680326A1 (en) * | 2007-03-13 | 2008-09-18 | Amgen Inc. | K-ras mutations and anti-egfr antibody therapy |
EP2118322A2 (en) * | 2007-03-13 | 2009-11-18 | Amgen Inc. | K-ras and b-raf mutations and anti-egfr antibody therapy |
-
2008
- 2008-03-11 EP EP08742064A patent/EP2118322A2/en not_active Withdrawn
- 2008-03-11 PL PL11184356T patent/PL2412828T3/pl unknown
- 2008-03-11 PE PE2008000450A patent/PE20090690A1/es not_active Application Discontinuation
- 2008-03-11 DK DK11184356.1T patent/DK2412828T3/da active
- 2008-03-11 ES ES11184356T patent/ES2426814T3/es active Active
- 2008-03-11 CL CL200800716A patent/CL2008000716A1/es unknown
- 2008-03-11 EP EP11184356.1A patent/EP2412828B1/en not_active Revoked
- 2008-03-11 PT PT111843561T patent/PT2412828E/pt unknown
- 2008-03-11 SI SI200831031T patent/SI2412828T1/sl unknown
- 2008-03-11 US US12/046,312 patent/US20090075267A1/en not_active Abandoned
- 2008-03-11 WO PCT/US2008/003327 patent/WO2008112274A2/en active Application Filing
- 2008-03-11 AR ARP080100994A patent/AR065686A1/es unknown
- 2008-03-11 CA CA002680330A patent/CA2680330A1/en not_active Abandoned
- 2008-03-11 TW TW097108518A patent/TW200904828A/zh unknown
- 2008-03-11 RS RS20130374A patent/RS52932B/en unknown
- 2008-03-11 AU AU2008226808A patent/AU2008226808B2/en not_active Ceased
- 2008-03-11 JP JP2009553625A patent/JP2010521154A/ja not_active Withdrawn
- 2008-03-11 MX MX2009009779A patent/MX2009009779A/es active IP Right Grant
-
2010
- 2010-05-17 HK HK12107511.1A patent/HK1167005A1/xx not_active IP Right Cessation
- 2010-12-22 US US12/976,895 patent/US20110212456A1/en not_active Abandoned
-
2013
- 2013-07-19 CY CY20131100612T patent/CY1114159T1/el unknown
- 2013-08-12 HR HRP20130764AT patent/HRP20130764T1/hr unknown
- 2013-09-12 JP JP2013189299A patent/JP5905422B2/ja active Active
-
2015
- 2015-02-23 JP JP2015032611A patent/JP2015119726A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2008112274A3 (en) | 2008-12-18 |
JP2010521154A (ja) | 2010-06-24 |
US20090075267A1 (en) | 2009-03-19 |
CL2008000716A1 (es) | 2008-09-22 |
CA2680330A1 (en) | 2008-09-18 |
HK1167005A1 (en) | 2012-11-16 |
PE20090690A1 (es) | 2009-06-22 |
AU2008226808A1 (en) | 2008-09-18 |
HRP20130764T1 (hr) | 2013-10-25 |
PL2412828T3 (pl) | 2013-11-29 |
WO2008112274A2 (en) | 2008-09-18 |
RS52932B (en) | 2014-02-28 |
TW200904828A (en) | 2009-02-01 |
MX2009009779A (es) | 2009-09-23 |
PT2412828E (pt) | 2013-08-02 |
EP2412828A1 (en) | 2012-02-01 |
EP2118322A2 (en) | 2009-11-18 |
US20110212456A1 (en) | 2011-09-01 |
JP5905422B2 (ja) | 2016-04-20 |
ES2426814T3 (es) | 2013-10-25 |
EP2412828B1 (en) | 2013-06-05 |
CY1114159T1 (el) | 2016-08-31 |
JP2013253105A (ja) | 2013-12-19 |
AU2008226808B2 (en) | 2013-04-18 |
JP2015119726A (ja) | 2015-07-02 |
DK2412828T3 (da) | 2013-09-02 |
AR065686A1 (es) | 2009-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1167005A1 (en) | K-ras and b-raf mutations and anti-egfr antibody therapy k-ras | |
SI2121989T1 (sl) | Mutacije k-ras in terapija s protitelesi anti-egfr | |
HK1136822A1 (en) | Therapeutic compounds and their use in cancer | |
GB0719803D0 (en) | Therapeutic compounds and their use | |
ZA200905886B (en) | Methods and kits for administering probiotics | |
EP2202913A4 (en) | USER AUTHENTICATION SYSTEM AND METHOD THEREOF | |
GB0719644D0 (en) | Therapeutic compounds and their use | |
EP2300011A4 (en) | METHODS AND THERAPEUTIC COMPOUNDS | |
GB0724251D0 (en) | Therapeutic compounds and their use | |
GB0722680D0 (en) | Therapeutic compounds and their use | |
EP2004637A4 (en) | SUBSTITUTED RING-CONDENSED AZINES AND THEIR USE IN CANCER THERAPY | |
EP2237792A4 (en) | ANTI-C35 ANTIBODY COMBINATION THERAPIES AND METHODS | |
GB0807018D0 (en) | Antibodies and treatment | |
GB2460178B (en) | Depsipeptides and their therapeutic use | |
GB0607946D0 (en) | Mono and combination therapy | |
GB0607949D0 (en) | Mono and combination therapy | |
GB2460181B (en) | Depsipeptides and their therapeutic use | |
HK1152038A1 (en) | Azetidine derivatives, their preparation and their application in therapy | |
EP2097085A4 (en) | THERAPEUTIC MATERIALS AND METHOD | |
EP2142648A4 (en) | SCREENING AND ANTI-NSCLC THERAPEUTIC METHOD TARGETING THE CDCA8-AURKB COMPLEX | |
GB2460180B (en) | Depsipeptides and their therapeutic use | |
EP2234667A4 (en) | DETERMINATION AND METHODS OF ADMINISTERING A TREATMENT | |
GB0818663D0 (en) | Gene regulation and its use in therapy | |
GB0705517D0 (en) | Therapeutic compounds and their use | |
GB0809328D0 (en) | Depsipeptides and their therapeutic use |